Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Abdominal migraine (AM) is a very common functional gastrointestinal disorder in children. This study reports the clinical features and response of AM to prophylactic treatment in children. Methods: This retrospective study was conducted between January 2010 and December 2019 at the Royal Hospital in the Sultanate of Oman. This study included children aged ≤ 13 years with a diagnosis of AM based on the Rome IV criteria for functional diagnoses. Clinical, demographic, and treatment data were collected. Results: Seventy-four children were identified, of which 43 were eligible for inclusion in this study. The median age at the onset of symptoms was 7 years (range, 2–12 years). The most frequent symptoms were headache (81.4%), nausea (79.1%), and vomiting (72.1%). Of the total cohort, 46.5%, 23.3%, and 6.9% received riboflavin, pizotifen, and propranolol monotherapy, respectively. Combination therapy was also used; 16.3% of children received pizotifen and propranolol, 4.7% received riboflavin and pizotifen, and 2.3% received riboflavin and propranolol. Patients treated with propranolol monotherapy showed 100% clinical improvement and those treated with riboflavin or pizotifen monotherapy showed 90% clinical improvement. Response to combination therapy with pizotifen and propranolol was 71.4%, and with riboflavin and pizotifen was 100%. In addition, treatment response was significantly associated with the presence of vomiting (p=0.039). Conclusion: We found a favorable response to various modalities and combination treatments with riboflavin, pizotifen, and propranolol in children with AM. In addition, the presence of vomiting may predict treatment response.
Abstract
Purpose: Abdominal migraine (AM) is a very common functional gastrointestinal disorder in children. This study reports the clinical features and response of AM to prophylactic treatment in children. Methods: This retrospective study was conducted between January 2010 and December 2019 at the Royal Hospital in the Sultanate of Oman. This study included children aged ≤ 13 years with a diagnosis of AM based on the Rome IV criteria for functional diagnoses. Clinical, demographic, and treatment data were collected. Results: Seventy-four children were identified, of which 43 were eligible for inclusion in this study. The median age at the onset of symptoms was 7 years (range, 2–12 years). The most frequent symptoms were headache (81.4%), nausea (79.1%), and vomiting (72.1%). Of the total cohort, 46.5%, 23.3%, and 6.9% received riboflavin, pizotifen, and propranolol monotherapy, respectively. Combination therapy was also used; 16.3% of children received pizotifen and propranolol, 4.7% received riboflavin and pizotifen, and 2.3% received riboflavin and propranolol. Patients treated with propranolol monotherapy showed 100% clinical improvement and those treated with riboflavin or pizotifen monotherapy showed 90% clinical improvement. Response to combination therapy with pizotifen and propranolol was 71.4%, and with riboflavin and pizotifen was 100%. In addition, treatment response was significantly associated with the presence of vomiting (p=0.039). Conclusion: We found a favorable response to various modalities and combination treatments with riboflavin, pizotifen, and propranolol in children with AM. In addition, the presence of vomiting may predict treatment response.
참고문헌 (19)
- Jeffrey S. Hyams, "Childhood Functional Gastrointestinal Disorders: Child", Adolescent, 2016, pp.150(6), 1456~1468.e2[DOI]
- Headache Classification Subcommittee of the International Headache Society, "The International Classification of Headache Disorders: 2nd edition", Cephalalgia, 24(1), pp.9~160 (2004)
- Headache Classification Committee of the International Headache Society(IHS), "The International Classification of Headache Disorders, 3rd edition(beta version)", Cephalalgia, 33, pp.629~808 (2013)
- Angus-Leppan H, "Abdominal migraine", BMJ, 360, pp.k179~ (2018)
- Abu-Arafeh I, "Prevalence and clinical features of abdominal migraine compared with those of migraine headache", Arch Dis Child, 72, pp.413~417 (1995)
- Carson L, "Abdominal migraine : an underdiagnosed cause of recurrent abdominal pain in children", Headache, 51, pp.707~712 (2011)
- Saps M, "Prevalence of functional gastrointestinal disorders in children and adolescents : comparison between Rome III and Rome IV criteria", J Pediatr, 199, pp.212~216 (2018)
- Mortimer MJ, "The VER as a diagnostic marker for childhood abdominal migraine", Headache, 30, pp.642~645 (1990)
- Saps M, "Prevalence of functional gastrointestinal disorders in Colombian school children", J Pediatr, 164, pp.542~545 (2014)[DOI]
- Korterink J, "Childhood functional abdominal pain : mechanisms and management", Nat Rev Gastroenterol Hepatol, 12, pp.159~171 (2015)
- Mani J, "Pediatric abdominal migraine : current perspectives on a lesser known entity", Pediatric Health Med Ther, 9, pp.47~58 (2018)
- Di Lorenzo C, "Chronic abdominal pain in children : a technical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition", J Pediatr Gastroenterol Nutr, 40, pp.249~261 (2005)
- Cuvellier JC, "Childhood periodic syndromes", Pediatr Neurol, 42, pp.1~11 (2010)
- Condò M, "Riboflavin prophylaxis in pediatric and adolescent migraine", J Headache Pain, 10, pp.361~365 (2009)
- Schoenen J, "Effectiveness of high-dose riboflavin in migraine prophylaxis", Neurology, 50, pp.466~470 (1998)
- Barbiroli B, "Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura", Neurology, 42, pp.1209~1214 (1992)
- Montagna P, "31P-magnetic resonance spectroscopy in migraine without aura", Neurology, 44, pp.666~669 (1994)
- Symon DN, "Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine", Arch Dis Child, 72, pp.48~50 (1995)
- Worawattanakul M, "Abdominal migraine : prophylactic treatment and follow-up", J Pediatr Gastroenterol Nutr, 28, pp.37~40 (1999)